Phase II study of pembrolizumab in advanced hepatocellular carcinoma as second-line treatment after failure of sorafenib: integration of genomic analysis to identify predictive molecular subtypes
Latest Information Update: 09 Aug 2022
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 25 Jan 2022 Status changed from recruiting to completed.
- 26 Dec 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.
- 17 May 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.